Skip to main content

Umbrella menu

  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Latest Articles
    • Issue Archive
    • Editorials
    • Research Highlights
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • EDITORIAL BOARD
  • BLOG
  • ABOUT
    • Overview
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

User menu

  • My alerts

Search

  • Advanced search
eNeuro
  • My alerts

eNeuro

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Latest Articles
    • Issue Archive
    • Editorials
    • Research Highlights
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • EDITORIAL BOARD
  • BLOG
  • ABOUT
    • Overview
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
PreviousNext
Research ArticleNew Research, Disorders of the Nervous System

Alterations in Cytosolic and Mitochondrial [U-13C]Glucose Metabolism in a Chronic Epilepsy Mouse Model

Tanya S. McDonald, Catalina Carrasco-Pozo, Mark P. Hodson and Karin Borges
eNeuro 10 February 2017, 4 (1) ENEURO.0341-16.2017; DOI: https://doi.org/10.1523/ENEURO.0341-16.2017
Tanya S. McDonald
1Department of Pharmacology, School of Biomedical Sciences, University of Queensland, St. Lucia, QLD 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catalina Carrasco-Pozo
1Department of Pharmacology, School of Biomedical Sciences, University of Queensland, St. Lucia, QLD 4072, Australia
2Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380453, Chile
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark P. Hodson
2Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380453, Chile
3Metabolomics Australia, Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St. Lucia, QLD 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark P. Hodson
Karin Borges
1Department of Pharmacology, School of Biomedical Sciences, University of Queensland, St. Lucia, QLD 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karin Borges
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Schematic of [U-13C]glucose in the brain. Simplified schematic of 13C-labeling patterns after the metabolism of [U-13C]glucose via glycolysis and the TCA cycle. Empty circles, 12C; black filled circle, 13C; gray filled circles, 13C derived from 13C-labeled oxaloacetate that enters the second turn of the TCA cycle (gray dotted lines). *Metabolites that were not measured in this study. GA3P, glyceraldehyde 3-phosphate; 13BPG, 1,3-bisphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; Ac-CoA, acetyl CoA; OAA, oxaloacetate.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Metabolism of [U-13C]glucose via glycolysis in SE mice in the chronic stage of pilocarpine model. A, Hippocampal 13C enrichment of glycolytic metabolites after i.p. injection of [U-13C]glucose was compared between SE and No SE mice. Reduced 13C enrichment in SE mice was found in G6P (22% reduction, p = 0.030), F6P (21%, p = 0.038), DHAP (17%, p = 0.05), and PEP (20%, p = 0.023). No significant differences were found in F16BP, 2 + 3PG, and PYR. Two-way ANOVA, SE status p < 0.001, n = 9–11 mice. B, The activities of all cytosolic enzymes, namely HK, PGI, PFK, PK, LDH, and G6PDH, were unaltered between control No SE mice and mice after SE within the chronic stage of the model (p > 0.05 for all); n = 7–9. C, Correlation analysis between percentage 13C enrichment of G6P and 13C enrichment in downstream metabolites in No SE mice. A significant correlation was observed with each metabolite, specifically: F6P, r = 0.89, p < 0.001; F16BP, r = 0.97, p < 0.001; DHAP r = 0.96, p < 0.001; 2 + 3PG, r = 0.76, p < 0.01; PEP, r = 0.96, p < 0.001; and PYR, r = 0.95, p < 0.001. No significant correlation was found between body weight (g) and percentage 13C enrichment of G6P, r = –0.28, p > 0.05. D, Correlation analysis between percentage 13C enrichment of G6P and 13C enrichment in downstream metabolites in SE mice. Similar to the No SE group, a strong correlation was observed with each downstream metabolite apart from 2 + 3PG. F6P, r = 0.91, p < 0.001; F16BP, r = 086, p < 0.001; DHAP, r = 0.90, p < 0.001; 2 + 3PG, r = 0.10, p > 0.05; PEP, r = 0.72, p < 0.05; and PYR, r = 0.64, p < 0.05. No significant correlation was found between body weight (g) and percentage 13C enrichment of G6P, r = –0.21, p > 0.05.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Metabolism of [U-13C]glucose via the TCA cycle is impaired in SE mice in the chronic stage of pilocarpine model. A, Percentage 13C enrichment in the TCA cycle metabolites from the first turn of the TCA cycle were compared between SE and No SE mice. Reduced 13C enrichment was found in CIT (17% reduction, p < 0.006), ACO (17%, p = 0.0001), SUC (35%, p = 0.005), and FUM (23%, p = 0.001) in the hippocampal formation of mice in the chronic epileptic state. No changes were found in the 13C enrichment of 2OG (p > 0.05) or MAL (p > 0.05). Two-way ANOVA, SE status p < 0.001, n = 9–11 mice. B, Percentage 13C enrichment of TCA cycle metabolites when labeled oxaloacetate condenses with [1,2-13C]acetyl CoA. A reduction in 13C enrichment was observed in the intermediates 2OG (47%, p = 0.03), SUC (55%, p = 0.037), FUM (25%, p = 0.044), and MAL (29%, p = 0.003). Two-way ANOVA, seizure status p < 0.001, n = 9–11 mice. C, Maximal activities of mitochondrial enzymes were compared between SE and No SE mice. SE mice had lower activity of both PDH (33%, p = 0.045) and 2-OGDH (55%, p = 0.027), two key enzymes involved in the entry and rate of TCA cycling, compared with No SE controls. No changes were found in the enzymes PCX, GDH, GPT, and GOT (all p > 0.05); n = 7–9 mice for all enzymes. D, Correlation analysis between percentage 13C enrichment in PYR to all first-turn TCA cycle intermediates in No SE mice. A significant correlation exists for all metabolites compared with PYR in this group. CIT, r = 0.86, p < 0.001; ACO, r = 0.80, p < 0.01; 2OG, r = 0.78, p < 0.01; SUC, r = 0.86, p < 0.01; FUM, r = 0.70, p < 0.05; and MAL, r = 0.91, p < 0.001. E, Correlation analysis of percentage 13C enrichment in SE mice between PYR and first-turn TCA cycle intermediates. No significant correlation was found between PYR and the TCA cycle metabolites. CIT, r = 0.34, p > 0.05; ACO, r = 0.54, p > 0.05; 2OG, r = 0.40, p > 0.05; SUC, r = 0.48, p > 0.05; FUM, r = 0.37, p > 0.05; and MAL, r = 0.46, p > 0.05. F, Correlation between percentage enrichment of 13C from the first turn of the TCA cycle between 2OG and SUC. A strong correlation was observed in 13C enrichment between the two metabolites in No SE mice (r = 0.95, p < 0.001), whereas no correlation was found in 13C enrichment of 2OG and SUC in SE mice (r = 0.42, p > 0.05).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Mitochondrial functional parameters of isolated hippocampal mitochondria from SE and No SE mice measured with the extracellular flux analyzer. A, Representation of the stages of the coupling assay to measure mitochondrial functions based on OCR. B, An example of the stages of the electron flow assay to measure electron flow through the electron transport chain base on the OCR. No differences were found in any of the parameters measured using the coupling assay state 2 respiration (C), state 3 respiration after the addition of ADP (D), state 3 uncoupled respiration (E), and respiration associated with ATP synthesis (F). Similarly, no significant differences were observed in the parameters measured using the electron flow assay including complex I–driven respiration (G) and complex II–driven respiration (H) between No SE and SE mice (n = 6–8 mice).

Tables

  • Figures
    • View popup
    Table 1.

    Analyte-dependent parameters for the transitions used in scheduled multiple reaction monitoring data acquisition

    AnalyteQ1 (Da) 12C analyteQ3 (Da) 12C analyteRT (min)DP (volts)CE (volts)CXP (volts)
    Glucose 6-phosphate258.8996.78.1–20–30–15
    Fructose 6-bisphosphate259.0296.89.6–20–30–15
    Fructose 1,6-bisphosphate339.0896.921.9–20–30–15
    Dihydroxyacetone phosphate168.849711.9–50–14–5
    2- and 3-Phosphoglycerate184.919721.5–50–20–5
    Phosphoenolpyruvate166.837922.3–40–18–5
    Pyruvate87.024311.9–45–12–1
    Citrate190.96110.922.6–50–18–7
    Aconitate172.9484.922.6–30–18–5
    2-Oxoglutarate144.95100.820.5–40–12–5
    Succinate1177318.5–45–16–3
    Fumarate115.0170.921.1–45–12–1
    Malate13370.819.7–40–22–3
    • View popup
    Table 2.

    Total levels of metabolites

    Metabolite (nmol/g tissue)No SE (n = 6–9)SE (n = 6–7)
    Glucose 6-phosphate20.1 ± 1.724.2 ± 3.4
    Fructose 6-phosphate33.0 ± 2.236.2 ± 5.9
    Fructose 1,6-bisphosphate16.5 ± 1.017.8 ± 1.4
    Dihydroxyacetone phosphate0.70 ± 0.080.67 ± 0.08
    2- and 3-Phosphoglycerate11.2 ± 1.010.9 ± 1.2
    Phosphoenolpyruvate8.93 ± 1.427.50 ± 1.33
    Pyruvate38.2 ± 2.734.2 ± 6.0
    Citrate109 ± 5110 ± 17
    Aconitate1.84 ± 0.122.24 ± 0.28
    2-Oxoglutarate90.8 ± 6.583.9 ± 17.4
    Succinate10.1 ± 0.88.1 ± 1.6
    Fumarate12.5 ± 0.913.2 ± 2.7
    Malate45.9 ± 3.946.1 ± 6.8
Back to top

In this issue

eneuro: 4 (1)
eNeuro
Vol. 4, Issue 1
January/February 2017
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Alterations in Cytosolic and Mitochondrial [U-13C]Glucose Metabolism in a Chronic Epilepsy Mouse Model
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Alterations in Cytosolic and Mitochondrial [U-13C]Glucose Metabolism in a Chronic Epilepsy Mouse Model
Tanya S. McDonald, Catalina Carrasco-Pozo, Mark P. Hodson, Karin Borges
eNeuro 10 February 2017, 4 (1) ENEURO.0341-16.2017; DOI: 10.1523/ENEURO.0341-16.2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Alterations in Cytosolic and Mitochondrial [U-13C]Glucose Metabolism in a Chronic Epilepsy Mouse Model
Tanya S. McDonald, Catalina Carrasco-Pozo, Mark P. Hodson, Karin Borges
eNeuro 10 February 2017, 4 (1) ENEURO.0341-16.2017; DOI: 10.1523/ENEURO.0341-16.2017
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • glucose
  • Glycolysis
  • metabolism
  • mitochondria
  • seizure
  • TCA cycle

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • Altered phosphorylation of the proteasome subunit Rpt6 has minimal impact on synaptic plasticity and learning
  • Social Experience Interacts with Serotonin to Affect Functional Connectivity in the Social Behavior Network following Playback of Social Vocalizations in Mice
  • Effects of optogenetic suppression of cortical input on primate thalamic neuronal activity during goal-directed behavior
Show more New Research

Disorders of the Nervous System

  • The Kainic acid models of Temporal Lobe Epilepsy
  • Interneuron Dysfunction in a New Mouse Model of SCN1A GEFS+
  • Time course of alterations in adult spinal motoneuron properties in the SOD1(G93A) mouse model of ALS
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2021 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.